CHAPEL HILL, N.C., May 18, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming investor conferences in Paris. Dr. Fernandes will present at the 18th Annual Euro-Biotech Forum at 9:45 a.m. CET, May 24, at the Hilton Arc de Triomphe. Dr. Fernandes will later present at BioEquity Europe 2011 at 3:00 p.m. CET, May 24, at the Paris Marriott Rive Gauche. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 [email protected]Tony Russo, Ph.D.Russo Partners, LLC(212) [email protected]
SOURCE Cempra Pharmaceuticals Inc.
Advertisement
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
Advertisement
Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 [email protected]Tony Russo, Ph.D.Russo Partners, LLC(212) [email protected]
SOURCE Cempra Pharmaceuticals Inc.
